Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Beam Irradiation and Brachytherapy

<table>Combined freedom from biochemical progression (using PSA nadir +2, PSA <svg height="8.8500004" id="M15" style="vertical-align:-0.30096pt" version="1.1" viewbox="0 0 16.0375 8.8500004" width="16.0375" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,8.85)">
<g transform="translate(72,-64.92)">
<text transform="matrix(1,0,0,-1,-71.95,65.27)">
<tspan style="font-size: 12.50px; " x="0" y="0">&lt;</tspan>
</text>
</g>
</g>
</svg> 0.2 at last follow-up) when evaluated for all 321 patients treated with PD-103 plus median 41 Gy beam radiation. (No significant variance was identified when plotting graphs using the two definitions.)  (<i>univariate analysis</i>).</table>

Journal of Oncology

fig1

Figure 1

Figure 1: Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Beam Irradiation and Brachytherapy 

Figure 1 | Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Beam Irradiation and Brachytherapy 